Navigation Links
Lupin Expands Branded Play
Date:9/29/2009

MUMBAI, India, Sept. 29 /PRNewswire-FirstCall/ -- Pharmaceutical Major, Lupin Ltd. announced today the acquisition of US rights for Antara® (Fenofibrate Capsules 43 mg and 130 mg). Lupin acquired the product from Oscient Pharmaceuticals on September 25, 2009, under the procedures of the U.S. Bankruptcy Court. Antara recorded net sales of US $ 70 million for 2008 (Source: IMS Dec 2008). Lupin paid $ 38.61 million for the product and related assets inclusive of inventory.

Lupin had previously filed an ANDA for Fenofibrate Capsules 43 mg and 130 mg. On September 21, 2009, prior to the acquisition of Antara®, Lupin sold its ANDA to Dr. Reddy's Laboratories. Lupin also settled and resolved the pending litigation regarding the ANDA product.

Prior to the acquisition, Antara® was marketed by Oscient Pharmaceuticals. Antara® has a strong brand equity with primary care physicians treating patients for high LDL-C, Total-C, triglycerides, Apo-B and low HDL-C. The Fenofibrate products market is $ 1.9 Billion for the last 12 months. Antara® has 4.5% share of this market and grew 20 % in revenue this past year. Antara® is prescribed for adjunct treatment of hypercholesterolemia (high blood cholesterol) and hyper-triglyceridemia (high triglycerides) in combination with diet.

The Antara acquisition enables Lupin to enter the primary care market with a three product portfolio. Lupin's Suprax Tabs and Allernaze have strong potential in primary care. Lupin will be more than doubling its sales force size in the next 12 months to reach the key targets for the three products.

"We are very excited with our 2nd NDA acquisition within a span of 4 months. The Antara® acquisition demonstrates Lupin's success in, and commitment to building its brand franchise and equity in the US. It underlines Lupin's differentiated strategy for the US market. Antara® is a step forward that will help us
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... YORK , Sept. 3, 2015 About dry ... dryness of eyes due to deficient tear production or ... syndrome is of two types: aqueous tear deficient dry ... dry eye, lacrimal glands do not produce enough tears, ... Meibomian glands secrete lipids to slow tear evaporation and ...
(Date:9/3/2015)... -- As part of its ongoing commitment to provide exceptional ... Katz , MD, MPH, cardiac surgeon and chief medical ... implanted the first HeartMate 3 left ventricular assist device ... part of the prestigious MOMENTUM 3™ Clinical Trial. Bon ... United States—and the first in central Virginia—chosen to evaluate ...
(Date:9/3/2015)... , Sep. 03, 2015 ... of the "Investigation Report on China,s Trastuzumab Market, ... by Genentech, trastuzumab was approved by FDA to be ... trade name of Herceptin, a major product of Roche. ... 6.56 billion around the world. After entering ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 3Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 4Investigation Report on China's Trastuzumab (Genentech) Market, 2010-2019 2
... Reportlinker.com announces that a new market research report ... Teva Pharma. Industries Ltd: PharmaVitae Profile ... This analysis examines the historical ... pharmaceutical sector. The profile encompasses global company strategy, ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), ... Zimmer NexGen LPS-Flex Mobile Bearing Knee with ... States.  The LPS-Flex Mobile Bearing knee provides a revolutionary anteriorly-positioned ... (ACL), replicating the anatomic center of knee rotation. ...
Cached Medicine Technology:Reportlinker Adds Teva Pharma. Industries Ltd: PharmaVitae Profile 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 3
(Date:9/3/2015)... , ... September 03, 2015 , ... ... and Indiana University, Indianapolis, have chosen Center for Hospice Care (CHC) for ... institutions will train at CHC as part of fulfilling their requirements for obtaining ...
(Date:9/3/2015)... Georgia (PRWEB) , ... September 03, 2015 , ... ... spread of disease in Haiti, has partnered with Slingshot® Product Development Group to ... electricity or running water. Michael Wahl with DriButts plans to bring 600 DriButts ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a ... Healthcare Research and Policy Analysis has found physician leadership development training programs to ... percent of respondents said their organizations conduct some kind of physician leadership development ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... care community to be situated at 4400 Columbine Drive in Bellingham, Washington. Silverado ... 2016, and has been carefully designed to serve up to 80 people living ...
(Date:9/3/2015)... ... September 03, 2015 , ... IQ Formulations ... 2015 by economic development group GrowFL and the Edward Lowe Foundation. The leading ... for this prestigious award, which recognizes growing second-stage companies “that demonstrate high performance ...
Breaking Medicine News(10 mins):Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:Site Dedication Ceremony to Celebrate New Silverado Memory Care Community 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3
... , ... skin brightener, has now introduced anti aging ingredients to its already popular product to make ... ... SkinBright the most complete skin brightener available. , , ,Age spots, liver spots, brown patches, ...
... ... to grow, unethical companies are beginning to produce imitation products to benefit from the success ... phony products before they become too large to control. , ... Milford, CT (PRWEB) March 16, 2010 -- They say imitation ...
... ... Marketing Excellence Europe Conference explores how global medical device manufacturers are leveraging integrated, domain-specific ... ... 16, 2010 -- Model N , the leader in Revenue Management solutions for ...
... ... income in the current economy, and who are looking to better their health, too, can ... enlisting interested business leaders nationwide., , ... (PRWEB) March 16, 2010 -- Independent businessman Brad Aspin and leading health and wellness ...
... NANJING , March 16 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... leading pharmaceutical company,specializing in the development, manufacturing, and marketing of ... for the quarter and the fiscal year ended December ... -- Total revenue was RMB539.4 million (US$79.0 million) ...
... Fla. , March 15 ARMSRx ... leader in transparent pharmacy benefits assessment, has received many requests ... the first quarter closes in 2010.  The September 26, ... First DataBank (FDB) and Medispan may very well leave employers ...
Cached Medicine News:Health News:Best Selling, Non Toxic Skin Brightener Does the Job Using Safe, Healthy Ingredients and Introduces New Anti Aging Ingredients 2Health News:IN Pet Supplements Face Challenges in New China Market as Imitation Products Continue to Baffle Consumers 2Health News:IN Pet Supplements Face Challenges in New China Market as Imitation Products Continue to Baffle Consumers 3Health News:Media Alert: Model N and International Medical Device Leader to Share Insights on Maximizing Sales Performance with Revenue Management 2Health News:Brad Aspin and Health and Wellness Company GBG Now Looking for Leaders Nationwide 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 12Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 14Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 15Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 16Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 17Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 18Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results 19Health News:ARMSRx Evaluation of AWP Neutrality 2Health News:ARMSRx Evaluation of AWP Neutrality 3
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... offer a complete line of ... state-of-the-art monoclonal and monoclonal/polyclonal antibody-based ... of enteric pathogens in fecal ... for Clostridium difficile, Entamoeba histolytica, ...
Inquire...
... CHEK test is a rapid immunoassay to detect ... specimens. The test uses antibodies specific for toxins ... >90% sensitivity and >99% specificity compared to tissue ... and toxin B, the risk of false negative ...
Medicine Products: